Novartis AG

Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: Results from a claims database analysis (2020) Rech J, Sticherling M, Stoessel D, Biermann MH, Häberle BM, Reinhardt M Journal article Correction to: Mode of action-based risk assessment of genotoxic carcinogens (Archives of Toxicology, (2020), 94, 6, (1787-1877), 10.1007/s00204-020-02733-2) (2020) Hartwig A, Arand M, Epe B, Guth S, Jahnke G, Lampen A, Martus HJ, et al. Journal article, Erratum Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors (2020) Pinter A, Kokolakis G, Rech J, Biermann MH, Häberle BM, Multmeier J, Reinhardt M Journal article Measurement of Skeletal Muscle Fiber Contractility with High-Speed Traction Microscopy (2020) Rausch M, Böhringer D, Steinmann M, Schubert DW, Schrüfer S, Mark C, Fabry B Journal article Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies (2019) Coates LC, Wallman JK, McGonagle D, Schett G, McInnes IB, Mease PJ, Rasouliyan L, et al. Journal article Psoriatic Arthritis - Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis (2019) Rech J, Sticherling M, Biermann M, Haeberle B, Reinhardt M Conference contribution Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES (2019) Schett G, Baraliakos X, Van Den Bosch F, Deodhar A, Gensler LS, Ostergaard M, Agawane S, et al. Conference contribution Psychiatric disorders are common comorbidities in patients with chronic spontaneous or inducible urticaria in Germany (2019) Weller K, Maurer M, Bauer A, Wedi B, Wagner N, Schliemann S, Baeumer D, et al. Conference contribution Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial (2019) Tahir H, Mease PJ, Kavanaugh A, Reimold A, Rech J, Hall S, Geusens P, et al. Conference contribution